The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Published:2023-04-13 Issue:12 Volume:55 Page:3167-3174
ISSN:1573-2584
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Ma Congyuan,Li Xuanwei,Li Wenlai,Li Yue,Shui Fangfang,Zhu Ping^ORCID

Funder

Hubei Provincial Department of Education Natural Science Research Project Fund

Yichang Medical and Health Research Project Fund

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

https://link.springer.com/content/pdf/10.1007/s11255-023-03586-1.pdf

Reference25 articles.

1. Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26(1):27–38. https://doi.org/10.1016/j.cmet.2017.04.011

2. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920

3. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744

4. Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, Koitka-Weber A (2019) Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial. Am J Kidney Dis 74(5):713–715. https://doi.org/10.1053/j.ajkd.2019.03.432

5. Tamura K, Wakui H, Azushima K, Uneda K, Umemura S (2016) Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. Hypert res 39(6):396–398. https://doi.org/10.1038/hr.2016.1

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?;Journal of Veterinary Pharmacology and Therapeutics;2024-07-13

2. Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies;International Urology and Nephrology;2024-07-04

3. Comment on “The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease”;International Urology and Nephrology;2024-01-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3